Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Flu season is ramping up, and some experts are "pretty worried" - 2New science points to 4 distinct types of autism
- 3Instructions to Pick the Right Gold Speculation Procedure: Exploring the Market
- 4Tech Patterns: Contraptions That Will Shape What's in store
- 52026 Golden Globes live updates: Red carpet arrivals will kick off the night; Nikki Glaser set to host
- Home Plan Tips for Seniors
- Flu illness count nears 5 million, with New York City among the hardest hit
- Palestinians forced from West Bank refugee camps left in limbo as Israeli demolitions go on
- Humanity is back at the moon! Artemis 2 astronauts arrive in lunar space
- Phenomenal Web-based MBA Stages for Proficient Headway
- 6 Arranging Administrations to Change Your Open air Space
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- Find Exemplary Scents: An Extensive Aide
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
